Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex announced its Q1 2021 results, reporting revenues of $633.9 million, a modest increase of 0.5% year-over-year. However, on a constant currency basis, revenues fell by 2.6%. The GAAP diluted EPS dropped 43.2% to $1.58, while adjusted diluted EPS rose by 5.5% to $2.87. The company raised its full-year revenue growth guidance but lowered its GAAP diluted EPS forecast. A restructuring plan is in place, expected to yield annual savings of $13 million to $16 million.
Teleflex (NYSE: TFX) announced that Liam Kelly, Chairman, President, and CEO, will speak at the Bank of America Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:00 a.m. (ET). A live audio webcast and presentation slides will be accessible on the investor section of the Teleflex website.
Teleflex is dedicated to medical technologies that enhance health and quality of life, with a diverse portfolio in areas like vascular access and emergency medicine. More information can be found at teleflex.com.
Teleflex Incorporated (NYSE: TFX) will announce its first quarter 2021 financial results before the market opens on April 29, 2021. An investor conference call is scheduled for 8:00 a.m. (ET) on the same day, accessible via a live audio webcast. A replay will be available from 11:00 a.m. on April 29 until May 6, 2021. Teleflex provides medical technologies aimed at improving patient health, focusing on innovation in various medical fields.
Teleflex is set to participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 24, 2021, at 9:15 AM (ET). Jake Elguicze, Treasurer and Vice President of Investor Relations, will present at the event. Investors can access a live audio webcast and slides on the company's website. Teleflex specializes in medical technologies aimed at improving health outcomes across various fields, including vascular access and anesthesia. For additional details, visit www.teleflex.com.
Teleflex announced that over 250,000 patients worldwide have been treated with the UroLift® System, a minimally invasive procedure for benign prostatic hyperplasia (BPH). In the U.S., BPH affects more than 42 million men, with about 12 million receiving treatment. The UroLift System differs from traditional options by providing rapid recovery and maintaining sexual function. Recent data reveal improved patient experiences with lower catheterization rates and higher satisfaction levels. The UroLift System has become a standard of care in urology practices, underscoring its effectiveness.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on March 15, 2021. Shareholders on record as of March 5, 2021 will receive this dividend. Teleflex focuses on providing medical technologies aimed at improving health outcomes, with a diverse portfolio that includes vascular access, cardiology, anesthesia, and more. For further details about their offerings, visit teleflex.com.
Teleflex reported fourth quarter 2020 revenues of $711.2 million, a 4.4% increase year-over-year, with adjusted diluted EPS of $3.25, down 0.9%. Full-year revenues fell 2.2% to $2.537 billion, alongside a 27.6% drop in GAAP diluted EPS to $7.10. The company estimates the COVID-19 pandemic had a $61 million negative impact on fourth-quarter revenue and $281 million for the full year. Looking ahead, 2021 guidance projects 10-11.5% revenue growth and adjusted diluted EPS between $12.50 and $12.70.
Teleflex Incorporated (NYSE: TFX) announced the submission of a Biologics License Application (BLA) for its investigational freeze dried plasma (FDP) candidate to the FDA. This candidate, developed in collaboration with the U.S. Army Medical Materiel Development Activity, aims to enhance emergency medical responses to battlefield injuries. The application is eligible for priority review and accelerated approval, facilitating potential rapid availability. The FDP is not yet FDA-approved. The announcement underscores Teleflex's innovation focus in medical technologies.
Teleflex Incorporated (NYSE: TFX) will be represented by CEO Liam Kelly at the Barclays Global Healthcare Conference on March 9, 2021, at 10:55 am ET. A live audio webcast of the event will be accessible on the investor section of Teleflex's website, along with a presentation slide deck. Teleflex specializes in medical technologies aimed at enhancing health and quality of life through innovative solutions in various medical fields, including vascular access and emergency medicine. For more information, visit www.teleflex.com.
Teleflex Incorporated (NYSE: TFX) has successfully completed patient enrollment ahead of schedule in its clinical study evaluating specialty catheters and coronary guidewires for Chronic Total Occlusion (CTO) percutaneous coronary interventions. The study enrolled 150 patients across 13 US sites, concluding three months early. CTOs affect nearly 20% of patients undergoing coronary angiography, often leading to severe ischemia and cardiac dysfunction. The study aims to assess device performance and safety, with expectations for results to inform clinical practices in CTO procedures.